FR20C1014I2 - Traitement de troubles du cycle sommeil-eveil - Google Patents

Traitement de troubles du cycle sommeil-eveil

Info

Publication number
FR20C1014I2
FR20C1014I2 FR20C1014C FR20C1014C FR20C1014I2 FR 20C1014 I2 FR20C1014 I2 FR 20C1014I2 FR 20C1014 C FR20C1014 C FR 20C1014C FR 20C1014 C FR20C1014 C FR 20C1014C FR 20C1014 I2 FR20C1014 I2 FR 20C1014I2
Authority
FR
France
Prior art keywords
sleep
treatment
wake cycle
cycle disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1014C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of FR20C1014I1 publication Critical patent/FR20C1014I1/fr
Application granted granted Critical
Publication of FR20C1014I2 publication Critical patent/FR20C1014I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR20C1014C 2005-06-08 2020-04-16 Traitement de troubles du cycle sommeil-eveil Active FR20C1014I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
PCT/US2006/022407 WO2006133393A1 (fr) 2005-06-08 2006-06-07 Traitement de troubles du cycle sommeil-eveil

Publications (2)

Publication Number Publication Date
FR20C1014I1 FR20C1014I1 (fr) 2020-06-12
FR20C1014I2 true FR20C1014I2 (fr) 2021-04-23

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1014C Active FR20C1014I2 (fr) 2005-06-08 2020-04-16 Traitement de troubles du cycle sommeil-eveil

Country Status (16)

Country Link
US (6) US8440715B2 (fr)
EP (1) EP1890684B1 (fr)
JP (1) JP5024635B2 (fr)
KR (1) KR101335941B1 (fr)
CN (1) CN101217949B (fr)
AU (1) AU2006254899B2 (fr)
BR (1) BRPI0613697A2 (fr)
CA (1) CA2611713C (fr)
DK (1) DK1890684T3 (fr)
ES (1) ES2435403T3 (fr)
FR (1) FR20C1014I2 (fr)
NL (1) NL301037I2 (fr)
PL (1) PL1890684T3 (fr)
RU (1) RU2417077C2 (fr)
TW (2) TW201328689A (fr)
WO (1) WO2006133393A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440715B2 (en) 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
ATE459393T1 (de) * 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
AU2010270971B2 (en) * 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496228B1 (fr) * 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Procédés pour traiter un trouble du déficit de l'attention avec hyperactivité
CA2779442A1 (fr) * 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Procedes pour traiter un syndrome de fibromyalgie
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
HUE060060T2 (hu) * 2013-03-13 2023-01-28 Jazz Pharmaceuticals Ireland Ltd Kataplexia kezelése
US9226910B2 (en) * 2013-07-18 2016-01-05 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2016061488A1 (fr) * 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Inhibiteurs de réabsorption d'amines
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR102513800B1 (ko) 2016-09-06 2023-03-24 에스케이바이오팜 주식회사 (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼
WO2018067971A1 (fr) 2016-10-06 2018-04-12 Jazz Pharmaceuticals International Iii Limited Composés de carbamoyl phénylalaninol et leurs utilisations
US10959976B2 (en) 2017-06-02 2021-03-30 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
WO2019027941A1 (fr) 2017-07-31 2019-02-07 Jazz Pharmaceuticals International Iii Limited Analogues de carbamoyl phénylalaninol et leurs utilisations
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) * 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
ZA943862B (en) 1993-06-10 1995-12-04 Lilly Co Eli Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz[cd] indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
DE69618663T2 (de) * 1996-10-10 2002-08-14 Sk Corp O-carbamoyl-phenylalaninol-zusammensetzungen und ihre pharmazeutisch anwendbaren salzen
WO1998017636A1 (fr) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Derives de phenylalaninol pour le traitement de troubles du systeme nerveux central
CZ20032299A3 (cs) * 2001-02-27 2004-08-18 Ortho@Mcneilápharmaceuticalźáinc Léčivo pro prevenci nebo léčbu motorických poruch
NZ546549A (en) * 2001-02-27 2007-11-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating anxiety disorders
KR100946944B1 (ko) * 2001-02-27 2010-03-15 오르토-맥네일 파마슈티칼, 인코퍼레이티드 양극성 장애의 예방 또는 치료용 카바메이트 화합물
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
MX2007005172A (es) 2004-10-28 2007-06-22 Sk Corp Terapia adjunta para la depresion.
US8440715B2 (en) * 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
ATE459393T1 (de) 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
KR101199499B1 (ko) 2005-07-26 2012-11-09 얀센 파마슈티카 엔.브이. 물질 관련 장애를 치료하는 방법
US20080090902A1 (en) 2006-10-13 2008-04-17 Pandey Ramendra N Phenylalkylamino carbamate compositions
AU2010270971B2 (en) 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
CA2779442A1 (fr) 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Procedes pour traiter un syndrome de fibromyalgie
EP2496228B1 (fr) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Procédés pour traiter un trouble du déficit de l'attention avec hyperactivité
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
HUE060060T2 (hu) * 2013-03-13 2023-01-28 Jazz Pharmaceuticals Ireland Ltd Kataplexia kezelése

Also Published As

Publication number Publication date
US20210078943A1 (en) 2021-03-18
US20090312416A1 (en) 2009-12-17
CN101217949A (zh) 2008-07-09
EP1890684A1 (fr) 2008-02-27
AU2006254899B2 (en) 2011-11-24
TW201328689A (zh) 2013-07-16
BRPI0613697A2 (pt) 2011-01-25
CA2611713A1 (fr) 2006-12-14
NL301037I1 (fr) 2020-04-01
JP2008545795A (ja) 2008-12-18
NL301037I2 (nl) 2020-05-12
KR101335941B1 (ko) 2013-12-04
US20130137764A1 (en) 2013-05-30
CN101217949B (zh) 2012-10-17
TWI419681B (zh) 2013-12-21
ES2435403T3 (es) 2013-12-19
JP5024635B2 (ja) 2012-09-12
TW200716084A (en) 2007-05-01
US9604917B2 (en) 2017-03-28
WO2006133393A1 (fr) 2006-12-14
US20190367448A1 (en) 2019-12-05
DK1890684T3 (da) 2013-10-14
FR20C1014I1 (fr) 2020-06-12
RU2417077C2 (ru) 2011-04-27
CA2611713C (fr) 2013-10-01
US10351517B2 (en) 2019-07-16
RU2008100019A (ru) 2009-07-20
US8440715B2 (en) 2013-05-14
PL1890684T3 (pl) 2014-05-30
US8877806B2 (en) 2014-11-04
KR20080035565A (ko) 2008-04-23
US20140350098A1 (en) 2014-11-27
US11753368B2 (en) 2023-09-12
EP1890684B1 (fr) 2013-08-14
AU2006254899A1 (en) 2006-12-14
US20170158622A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
FR20C1014I2 (fr) Traitement de troubles du cycle sommeil-eveil
FR21C1063I1 (fr) Traitement combiné de tumeurs exprimant la cd38
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
FR2912833B1 (fr) Panneau pour le traitement acoustique
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
FR2901405B1 (fr) Appareils de traitement
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
FR2876047B1 (fr) Traitement de polluants par phytolixiviation
BRPI0716466A2 (pt) Tratamento da calda de açúcar
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
FR2928832B1 (fr) Orthese de poignet, destinee au traitement du syndrome du canal carpien
ATE465150T1 (de) Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate
DK1962869T3 (da) Behandling af luftvejssygdomme
FR2900336B1 (fr) Composition de lavage des matieres keratiniques et procede de traitement cosmetique mettant en oeuvre ladite composition
FR2884647B1 (fr) Traitement de plaques de semi-conducteurs
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
BRPI0715728A8 (pt) tratamento de distúrbios cartilaginosos
IL196449A0 (en) Device for physiotherapeutic treatment of diseases of various etiology
FR2943537B1 (fr) Traitement des nevrites vestibulaires par l'acetyl-l-leucine
DK1940447T3 (da) Behandling af neurodegenrative lidelser
ITVR20050112A1 (it) Lettino per massaggi
FR2908965B1 (fr) Ensemble cosmetique et procede de traitement cosmetique
DE602004011679D1 (de) Behandelung von Störungen
DE602007003350D1 (de) Behandlung von polysilazan-abfall